These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33970849)

  • 21. Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report.
    Chouinard G; Bélanger MC; Beauclair L; Sultan S; Murphy BE
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Aug; 20(6):1067-79. PubMed ID: 8888111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice.
    Sugimoto Y; Tagawa N; Kobayashi Y; Hotta Y; Yamada J
    Biol Pharm Bull; 2007 Dec; 30(12):2399-401. PubMed ID: 18057733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased serotonergic neurotransmission is not responsible for the anticompulsive effect of berberine in a murine model of obsessive-compulsive disorder.
    Dixit PV; Parihar G; Jain DK; Jaiswal P
    Behav Pharmacol; 2012 Oct; 23(7):716-21. PubMed ID: 22890212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.
    Umathe SN; Manna SS; Jain NS
    Behav Brain Res; 2011 Sep; 223(1):125-34. PubMed ID: 21549765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
    Todorov C; Freeston MH; Borgeat F
    Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.
    Wald R; Dodman N; Shuster L
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):191-7. PubMed ID: 19586234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marble-burying behavior test as a murine model of compulsive-like behavior.
    Dixit PV; Sahu R; Mishra DK
    J Pharmacol Toxicol Methods; 2020; 102():106676. PubMed ID: 31954839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postpartum Lactation-Mediated Behavioral Outcomes and Drug Responses in a Spontaneous Mouse Model of Obsessive-Compulsive Disorder.
    Mitra S; Mucha M; Owen S; Bult-Ito A
    ACS Chem Neurosci; 2017 Dec; 8(12):2683-2697. PubMed ID: 28945961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Animal models of obsessive-compulsive disorder.
    Witkin JM
    Curr Protoc Neurosci; 2008 Oct; Chapter 9():Unit 9.30. PubMed ID: 18972380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.
    Kampman M; Keijsers GP; Hoogduin CA; Verbraak MJ
    Acta Psychiatr Scand; 2002 Oct; 106(4):314-9. PubMed ID: 12225499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
    den Boer JA
    J Clin Psychiatry; 1997; 58 Suppl 8():17-9. PubMed ID: 9236731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine.
    Egashira N; Harada S; Okuno R; Matsushita M; Nishimura R; Mishima K; Iwasaki K; Orito K; Fujiwara M
    Eur J Pharmacol; 2007 Jun; 563(1-3):149-54. PubMed ID: 17349995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
    Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
    J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Celecoxib potentiates the antianxiety and anticompulsive-like activity of fluoxetine against chronic unpredictable mild stress in experimental animals.
    Garabadu D; Kumar V
    Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):251-259. PubMed ID: 30724800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder.
    el Mansari M; Bouchard C; Blier P
    Neuropsychopharmacology; 1995 Oct; 13(2):117-27. PubMed ID: 8597523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of aripiprazole and ethanol attenuates marble-burying behavior in mice.
    Gaikwad U; Parle M
    Acta Pol Pharm; 2011; 68(3):435-40. PubMed ID: 21648199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.